Drug packaging in 2009: a few advances.
Once again, in 2009, most of the packaging that Prescrire analysed did not meet our quality criteria. Labelling information was too often ambiguous or clumsily expressed. The quality of dosing devices and the safety of multidose bottles were not guaranteed. Patient information leaflets were more legible on the whole, but once again rather uninformative. All of these shortcomings put patients at risk. European measures concerning drug labelling have finally been transposed into French law, and have led to some improvements: the international nonproprietary name (INN) is more frequently displayed on primary packaging. The use of Braille on boxes and access to Braille package leaflets are increasing. The improved legibility of the labelling of ampoules containing certain dangerous injectable drugs, as recommended by the French drug regulatory agency (Afssaps), has become more widespread. In practice, healthcare professionals need to take action on packaging issues: by choosing the best packaging, reporting potential sources of confusion and error and informing patients.
D004348:Drug Labeling / Q000592:standards; D004349:Drug Packaging / Q000592:standards